Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
FDA grant of RMAT designation to Allocetra™ reinforces the potential of this program to deliver a meaningful, disease-modifying impact in age-related primary knee osteoarthritis, where patients face...
-
NEEDHAM, Mass., July 08, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...
-
Vaccinex reports new biomarker research and plans for Phase 2 randomized clinical trial of pepinemab in Alzheimer's Disease at the AAIC in July
-
The Alberta Cancer Foundation is investing $35-million to advance cancer clinical trials in Alberta.
-
Dublin, July 03, 2026 (GLOBE NEWSWIRE) -- The "Rituximab Sales Forecast, and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering. Key Factors Driving Rituximab...
-
NEEDHAM, Mass., July 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...
-
LONDON and BOSTON and BUDAPEST, Hungary, June 09, 2026 (GLOBE NEWSWIRE) -- Treos Bio, a clinical-stage company developing off-the-shelf and personalized active cancer immunotherapies, today...
-
EnGeneIC Honored with 2026 Breakthrough in glioblastoma Biotech Award at Northwell Foundation Lenox Hill Neurosurgery Brain Cancer Gala in New York
-
At the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) which will this year take part in Istanbul, Türkiye from 12 to 15 June 2026, the Danish pharmaceutical company...
-
Nouscom receives FDA Fast Track Designation for NOUS-209, advancing development of its cancer-prevention immunotherapy for Lynch Syndrome carriers.